AzTrials
AzTrials

PsoriasisPhase 4METABOLYXNCT03440736

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

A Phase 4 study testing Secukinumab and Life-style intervention in people with Psoriasis and Metabolic Syndrome, run by Novartis Pharmaceuticals at 75 sites in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could primarily improve skin symptoms and secondly cardiometabolic status more than Secukinumab alone in… Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Psoriasis, Metabolic Syndrome
What is being tested?
Secukinumab and Life-style intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
781 participants
Where
75 sitesGermany
Study dates
28 Feb 2018to 3 Jun 2022
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Written informed consent must be obtained before any assessment is performed.
  • Men or women of at least 18 years of age at the time of screening.
  • Patients must be able to understand and communicate with the investigator and must be willing and able to comply with all study procedures.
  • Patients with moderate to severe plaque-type psoriasis who are candidates for systemic therapy, diagnosed at least 6 month before randomization and baseline value of
  • PASI > 10 and
  • DLQI > 10 and
Show all 14Show fewer
  • Body Surface Area (BSA) affected by plaque-type psoriasis ≥ 10%
  • Fulfillment of Metabolic Syndrome definition (Alberti et al., 2009), which means fulfillment of ≥3 of the following criteria at screening visit:
  • Fasting (8 hours) plasma glucose ≥ 100 mg/dl or ongoing antidiabetic drug treatment (defined as: metformin, DPP4 inhibitors, GLP1 analogues, SGLT2 inhibitors)
  • Abdominal obesity defined by elevated waist circumference (measured as defined in section 6.4.5): Male: ≥94 cm, female: ≥80 cm (except for patients of Asian, South or Central American ethnicity, for whom the cut off values are: Male: ≥90 cm, female: ≥80 cm)
  • Fasting (8 hours) triglycerides ≥ 150 mg/dl or ongoing drug treatment for elevated triglycerides (defined as: fibrates or nicotinic acid).
  • Fasting (8 hours) HDL-C < 40 mg/dl in men or < 50 mg/dl in women or ongoing drug treatment for reduced HDL-C (defined as: fibrates, nicotinic acid or statins).
  • Resting blood pressure: Systolic blood pressure ≥ 130 and/ or diastolic blood pressure ≥ 85 mmHg (measured as defined in section 6.4.6) or ongoing antihypertensive drug treatment [defined as: ACE inhibitors, beta blockers, angiotensin receptor antagonists (e.g. Valsartan), aldosterone receptor antagonists, diuretics, nitrates, calcium channel blockers (e.g. Verapamil, Nifedipin), Aliskiren, Clonidin, alpha1 receptor antagonists (e.g. Doxazosin), Dihydralazin, Minoxidil, Moxonidin or Methyldopa].
  • Willingness and motivation to actively participate in a lifestyle intervention, which means patients need to be willing to increase physical activity and to change dietary habits.

Who cannot join

  • Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients.
  • Forms of psoriasis other than chronic plaque-type (e.g. pustular, erythrodermic and guttate psoriasis) at screening.
  • Previous exposure to Secukinumab or any other biologic drug directly targeting IL17A or the IL17A receptor (e.g. Brodalumab, Ixekizumab).
  • Exposure to anti-TNF treatment during 1 year prior to baseline.
  • Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium) at screening.
  • History of hypersensitivity to Secukinumab, trehalose-dihydrate, L-histidine, L-histidinhydrochloride-monohydrate, L-methionine, polysorbate 80, water for injection, or to substances of similar chemical classes.
Show all 37Show fewer
  • History of latex hypersensitivity.
  • Ongoing participation (including safety follow-up period) in other interventional or non-interventional studies in any dermatological indication
  • Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to (Table 5-1). Note: Administration of live vaccines 6 weeks prior to baseline (visit 2) or during the study period is also prohibited.
  • Diagnosis of type 1 diabetes.
  • Patients with diagnosed type 2 diabetes, if they fulfill one or more of the following conditions:
  • uncontrolled type 2 diabetes, meaning HbA1c > 8.0%,
  • pharmacological therapy with one or more of the following agents: Insulin, sulfonylurea agents/analogues, thiazolidinediones/glitazones
  • Insufficiently controlled, severe arterial hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 95 mmHg) with urgent need for therapy initiation or foreseeable need for medication change during the duration of the core study.
  • Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis (PsA) that might confound the evaluation of the benefit of Secukinumab therapy.
  • Underlying conditions (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy.
  • Significant, progressive or uncontrolled medical problems at baseline which according to the opinion of the Investigator render the subject unsuitable for the trial - also in regard to participation in the lifestyle intervention - or put the subject at increased risk when participating in the trial (e.g. broken leg, congestive heart failure NYHA III/IV, uncontrolled hypertension with systolic ≥ 160 mmHg and/or diastolic ≥ 95 mmHg, severe uncontrolled asthma)
  • Medical history of myocardial infarction or angina pectoris
  • Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
  • Serum creatinine level exceeding 2.0 mg/dl (176.8 μmol/L) at screening
  • Total white blood cell (WBC) count < 2,500/μl, or platelets < 100,000/μl or neutrophils < 1,500/μl or hemoglobin < 8.5 g/dl at screening.
  • Active systemic infections during the last two weeks (exception: common cold) prior to baseline (visit 2) or any infection that reoccurs on a regular basis.
  • History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold test (QFT) at screening. Subjects with a positive or indeterminate QFT test may participate in the study if full tuberculosis work up (according to local practice/guidelines) was completed within 12 weeks prior to visit 2 and establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then appropriate treatment must have been initiated at least 4 weeks prior to baseline (visit 2) and maintained according to local guidelines.
  • Past medical history record or current infection with HIV, hepatitis B or hepatitis C prior to baseline (visit 2).
  • History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks prior to baseline (visit 2); carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
  • Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor tolerability or lack of access to veins).
  • History or evidence of ongoing alcohol or drug abuse, within the last six months before baseline (visit 2).
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception during dosing of investigational drug for at least 20 weeks after the end of Secukinumab treatment. Basic contraception methods include:
  • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
  • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
  • Male sterilization (at least 6 m prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject
  • Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps).
  • Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS)
  • In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking investigational drug.
  • Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

Trial locations and contacts

75 sites in 1 country.

75 sites in 1 country

Germany75 sites

  • Novartis Investigative Site

    Andernach, 56626

  • Novartis Investigative Site

    Augsburg, 86179

  • Novartis Investigative Site

    Bad Soden, 65812

  • Novartis Investigative Site

    Berlin, 10117

  • Novartis Investigative Site

    Berlin, 10783

  • Novartis Investigative Site

    Berlin, 10789

  • Novartis Investigative Site

    Berlin, 13055

  • Novartis Investigative Site

    Berlin, 13088

  • Novartis Investigative Site

    Berlin, 13125

  • Novartis Investigative Site

    Berlin, 13187

  • Novartis Investigative Site

    Berlin, 13353

  • Novartis Investigative Site

    Berlin, 13507

  • Novartis Investigative Site

    Berlin, 13597

  • Novartis Investigative Site

    Bielefeld, 33647

  • Novartis Investigative Site

    Bochum, 44791

  • Novartis Investigative Site

    Bochum, 44793

  • Novartis Investigative Site

    Bonn, 53105

  • Novartis Investigative Site

    Bramsche, Lower Saxony, 49565

  • Novartis Investigative Site

    Braunschweig, 38100

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50937

  • Novartis Investigative Site

    Darmstadt, Hesse, 64283

  • Novartis Investigative Site

    Darmstadt, 64283

  • Novartis Investigative Site

    Detmold, North Rhine-Westphalia, 32756

  • Novartis Investigative Site

    Dresden, Saxony, 01307

  • Novartis Investigative Site

    Dresden, 01097

  • Novartis Investigative Site

    Düsseldorf, North Rhine-Westphalia, 40225

  • Novartis Investigative Site

    Düsseldorf, 40212

  • Novartis Investigative Site

    Erlangen, 91054

  • Novartis Investigative Site

    Falkensee, 14612

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590

  • Novartis Investigative Site

    Freiburg im Breisgau, 79098

  • Novartis Investigative Site

    Friedrichshafen, 88045

  • Novartis Investigative Site

    Gera, 07548

  • Novartis Investigative Site

    Göttingen, Lower Saxony, 37075

  • Novartis Investigative Site

    Greifswald, 17475

  • Novartis Investigative Site

    Hagen, 58095

  • Novartis Investigative Site

    Halle, Saxony-Anhalt, 06108

  • Novartis Investigative Site

    Hamburg, 22303

  • Novartis Investigative Site

    Hamburg, 22391

  • Novartis Investigative Site

    Hanau, 63450

  • Novartis Investigative Site

    Hanover, 30625

  • Novartis Investigative Site

    Ibbenbueren, 49477

  • Novartis Investigative Site

    Kiel, 24105

  • Novartis Investigative Site

    Langenau, Baden-Wurttemberg, 89129

  • Novartis Investigative Site

    Leipzig, Saxony, 04103

  • Novartis Investigative Site

    Leipzig, Saxony, 04207

  • Novartis Investigative Site

    Lingen, Lower Saxony, 49809

  • Novartis Investigative Site

    Löhne, 32584

  • Novartis Investigative Site

    Lüdenscheid, 58515

  • Novartis Investigative Site

    Magdeburg, 39104

  • Novartis Investigative Site

    Magdeburg, 39120

  • Novartis Investigative Site

    Mainz, 55131

  • Novartis Investigative Site

    Memmingen, 87700

  • Novartis Investigative Site

    Mönchengladbach, 41061

  • Novartis Investigative Site

    München, 80377

  • Novartis Investigative Site

    Munich, Bavaria, 80469

  • Novartis Investigative Site

    Munich, Bavaria, 81377

  • Novartis Investigative Site

    Münster, 48149

  • Novartis Investigative Site

    Oberhausen, 46147

  • Novartis Investigative Site

    Oldenburg, 26133

  • Novartis Investigative Site

    Osnabrück, 49074

  • Novartis Investigative Site

    Plauen, 08529

  • Novartis Investigative Site

    Pommelsbrunn, 91224

  • Novartis Investigative Site

    Potsdam, 14467

  • Novartis Investigative Site

    Quedlinburg, 06484

  • Novartis Investigative Site

    Remscheid, 42897

  • Novartis Investigative Site

    Seligenstadt, 63500

  • Novartis Investigative Site

    Selters, 56242

  • Novartis Investigative Site

    Simmern, 55469

  • Novartis Investigative Site

    Soest, 59494

  • Novartis Investigative Site

    Stuttgart, 70178

  • Novartis Investigative Site

    Ulm, 89081

  • Novartis Investigative Site

    Vechta, 49377

  • Novartis Investigative Site

    Wuppertal, 42109

  • Novartis Investigative Site

    Wuppertal, 42349

Other trials in Germany

About this study

Official title: A Randomized, Multicenter 28 Week Study to Compare the Efficacy and Safety of Combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) With a Lifestyle Intervention to Cosentyx Therapy Alone in Adult Patients With Moderate to Severe Plaque-type Psoriasis and Concomitant Metabolic Syndrome, Followed by a 28 Week Extension Period

This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could primarily improve skin symptoms and secondly cardiometabolic status more than Secukinumab alone in psoriasis patients with concomitant metabolic syndrome by targeting the shared pathophysiology behind both diseases, which is systemic inflammation.

Read the detailed description

This study included Core study with a duration of 28 weeks followed by an Extension period (exploratory period) with a duration of 28 weeks.

Core study:

After providing informed consent, patients were screened for eligibility for a period of 1 to 4 weeks prior to inclusion in the study. Eligible patients were randomized to one of the two treatment arms, which were the following:

  • Arm A: Patients in arm A received a regular induction followed by 4-weekly maintenance treatment with secukinumab 300 mg s.c. until Week 28, where they completed the core study. The last secukinumab injection was to be administered at Week 24.
  • Arm B: Patients in arm B received a regular induction followed by 4-weekly maintenance treatment with secukinumab 300 mg s.c. until Week 28. The last secukinumab injection was to be administered at Week 24. In addition to secukinumab treatment, patients in arm B participated in a lifestyle intervention program.

A biomarker sub-study was conducted during the core study in a subgroup of 100 patients (50 from each treatment arm).

The core study ended at Week 28.

Extension period (exploratory period):

After 28 weeks, the study continued with an extension period, during which lifestyle intervention was offered to all patients, irrespective of their prior treatment arm. This meant that patients of arm B, who were willing to, could continue their previously started lifestyle intervention program, and patients of arm A, who were willing to, could start the lifestyle intervention program at the beginning of the extension period. All patients, irrespective of their decision whether to start/continue lifestyle intervention or not, had to participate in the extension period and visit their dermatologic study center for scheduled visits. The extension period ended at Week 56, where all patients completed the study. No study drug was supplied during the extension period. The treating physician could choose psoriasis therapy freely according to their discretion.

Being tested
Secukinumab, Life-style intervention
Keywords
Psoriasis, Metabolic syndrome, Diabetes, Obesity, Life-style, Life-style intervention, Secukinumab, CAIN457A, CAIN457ADE08, AIN457A, Skin condition, skin disease, itching condition, psoriasis vulgaris, relapsing psoriasis, remitting psoriasis, immune-mediated systemic disease, skin lesions, red skin lesions, scaly patches
Medical subject headings
Psoriasis, Metabolic Syndrome, Diabetes Mellitus, Obesity, Skin Diseases, Plaque, Amyloid, Pruritus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SecukinumabDrug

    Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)

  • Life-style interventionBehavioural

    A structured program to guide weight loss and increased physical activity

Study groups in NCT03440736
Study groupRoleWhat they receive
Secukinumab 300 mg subcutaneous (s.c.)Active comparatorPatients in arm A received therapy with Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24).
Receives: Drug: Secukinumab
Secukinumab 300 mg subcutaneous (s.c.) and lifestyle interventionExperimentalPatients in arm B received therapy with Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24). In addition they participated in a lifestyle intervention program.
Receives: Drug: Secukinumab; Behavioral: Life-style intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Patients Achieving Psoriasis Area and Severity Index (PASI) Score of 90 at Week 28

    The Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs, lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    PASI 90 represents patients achieving >= 90% improvement (reduction) in PASI score compared to Baseline. Patients with missing PASI at Week 28 were counted as non-responders.

    Measured: Baseline, Week 28

Secondary outcomes (24)

  1. Percentage of Patients Achieving Psoriasis Area and Severity Index (PASI) Score of 75 Over Time

    The Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs, lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    PASI 75 represents patients achieving >= 75% improvement (reduction) in PASI score compared to Baseline.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  2. Percentage of Patients Achieving Psoriasis Area and Severity Index (PASI) Score of 90 Over Time

    The Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs, lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    PASI 90 represents patients achieving ≥ 90% improvement (reduction) in PASI score compared to Baseline.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24

  3. Percentage of Patients Achieving Psoriasis Area and Severity Index (PASI) Score of 100 Over Time

    The Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs, lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    PASI 100 response/remission represents patients achieving complete clearing of psoriasis (PASI = 0) compared to Baseline.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  4. Mean Difference From Baseline in Absolute Psoriasis Area and Severity Index (PASI) Score Over Time

    The Psoriasis Area and Severity Index (PASI) combines lesion severity and the extent of affected area into a single score ranging from 0 (no disease) to 72 (maximum disease). The body is divided into four regions for scoring: head, trunk, upper limbs, and lower limbs. Each region is scored individually, and these scores are then combined to calculate the final PASI. For each region, the percentage of skin involved is estimated on a scale from 0 (0%) to 6 (90-100%), and severity is assessed based on clinical signs such as erythema, induration, and desquamation, on a scale from 0 (none) to 4 (maximum). The final PASI is the sum of the severity parameters for each area multiplied by the area score weight of the section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). A negative change in the absolute PASI score indicates a reduction in psoriasis severity, signifying an improvement in the patient's condition.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  5. Mean Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)

    High-sensitivity C-reactive Protein (hsCRP) was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  6. Mean Change From Baseline in Hemoglobin A1c (HbA1c)

    Hemoglobin A1c (HbA1c) was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 8, Week 16, Week 24, Week 28

  7. Mean Change From Baseline in Fructosamine

    Fructosamine was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  8. Mean Change From Baseline in Fasting Plasma Glucose (FPG)

    Fasting Plasma Glucose (FPG) was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 8, Week 16, Week 28

  9. Mean Change From Baseline in Total Cholesterol

    Total cholesterol was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 8, Week 16, Week 28

  10. Mean Change From Baseline in Low-Density Lipoprotein (LDL)

    Low-Density Lipoprotein (LDL) was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 8, Week 16, Week 28

  11. Mean Change From Baseline in High-Density Lipoprotein (HDL)

    High-Density Lipoprotein (HDL) was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 8, Week 16, Week 28

  12. Mean Change From Baseline in Triglycerides

    Triglycerides were evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 8, Week 16, Week 28

  13. Mean Change From Baseline in Waist Circumference

    Waist circumference was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  14. Mean Change From Baseline in Body Weight

    Body weight was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  15. Mean Change From Baseline in Body Mass Index (BMI)

    Body Mass Index (BMI) was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  16. Mean Change From Baseline in Systolic Blood Pressure (SBP)

    Systolic Blood Pressure was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  17. Mean Change From Baseline in Diastolic Blood Pressure (DBP)

    Diastolic Blood Pressure was evaluated in both treatment arms throughout the duration of the core study and summarized using descriptive statistics.

    Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  18. Dermatology Life Quality Index (DLQI) Total Score Over Time

    The Dermatology life Quality Index (DLQI) is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. Each question refers to the impact of the skin disease on the patient's life (symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, treatment) over the previous week and is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

    Measured: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  19. Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score Over Time

    The Dermatology life Quality Index (DLQI) is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. Each question refers to the impact of the skin disease on the patient's life (symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, treatment) over the previous week and is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

    Measured: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  20. Percentage of Patients With Dermatology Life Quality Index (DLQI) Response

    All patients with DLQI score 0 and 1 were considered as responders and patients with DLQI score >=2 were considered as non-responders. Subjects with missing DLQI score were counted as non-responders.

    Measured: Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  21. World Health Organization Well-Being Index (WHO-5) Total Score Over Time

    The 5-item World Health Organization Well-Being Index (WHO-5) is a validated, short questionnaire consisting of 5 simple questions, assessing subjective psychological well-being of the respondents. The recall period is the previous two weeks. Each item has 6 response categories, ranging from 5 ("the whole time") to 0 ("at no time point"). The WHO-5 total score is the sum of the 5 questions and ranges from 0 to 25, with 0 representing worst possible and 25 representing best possible quality of life.

    Measured: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  22. Mean Change From Baseline in World Health Organization Well-Being Index (WHO-5) Total Score Over Time

    The 5-item World Health Organization Well-Being Index (WHO-5) is a validated, short questionnaire consisting of 5 simple questions, assessing subjective psychological well-being of the respondents. The recall period is the previous two weeks. Each item has 6 response categories, ranging from 5 ("the whole time") to 0 ("at no time point"). The WHO-5 total score is the sum of the 5 questions and ranges from 0 to 25, with 0 representing worst possible and 25 representing best possible quality of life.

    Measured: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  23. Participant's Self-assessed Pain, Itching and Scaling Over Time

    A self-administered, 11-point numeric rating scale (NRS, 0-10) was used to evaluate the subject's assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment of:

    • Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours
    • Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours
    • Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours Subjects had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represented the absence or null end of the pain, itching, or scale intensity (i.e., no pain, itching or scaling) and the 10 represented the other extreme of pain, itching, or scaling intensity (i.e., pain, itching or scaling as bad as it could be). The number that the patient selected represented his or her intensity score.

    Measured: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

  24. Percentage Change From Baseline in Participant's Self-assessed Pain, Itching and Scaling

    A self-administered, 11-point numeric rating scale (NRS, 0-10) was used to evaluate the subject's assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment of:

    • Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours
    • Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours
    • Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours Subjects had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represented the absence or null end of the pain, itching, or scale intensity (i.e., no pain, itching or scaling) and the 10 represented the other extreme of pain, itching, or scaling intensity (i.e., pain, itching or scaling as bad as it could be). The number that the patient selected represented his or her intensity score.

    Measured: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Feb 2018
  2. Study start28 Feb 2018
  3. Primary completion30 Nov 2021
  4. Study completion3 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
781 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03440736
Sponsor's protocol ID
CAIN457ADE08
Other IDs
2016-001671-79, 2016
Acronym
METABOLYX
Status last verified
Apr 2026
First submitted
31 Jan 2018
Last updated
22 Apr 2026
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Secukinumab and Life-style intervention in people with Psoriasis and Metabolic Syndrome, run by Novartis Pharmaceuticals at 75 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 75 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Apr 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Patients Achieving Psoriasis Area and Severity Index (PASI) Score of 90 at Week 28 (time frame: Baseline, Week 28). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03440736.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in